دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Diabetes: knowing your risk matters
doi : 10.1016/S2213-8587(23)00326-1
Volume 11, Issue 12, December 2023, Page 879
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY
doi : 10.1016/S2213-8587(23)00263-2
Volume 11, Issue 12, December 2023, Pages 880-881
Impact of disease-modifying therapy on β-cell function and metabolic control in newly diagnosed type 1 diabetes
Mikael Knip a
Glycaemic fluctuations across the menstrual cycle: possible effect of the brain
Julia Hummel a, Stephanie Kullmann b c d, Róbert Wagner d e f, Martin Heni a g
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction
Stephen M Twigg a b, Luigi Fontana a b
Tackling the diabetes surge in sub-Saharan Africa through novel youth-centric strategies
Felix P Chilunga a, Asanda Mtintsilana b, Pearl Aovare c, George Msengi d, George F Mkoma e, Wisdom Nakanga f
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries
Ranjit Mohan Anjana a, Nirmal Elangovan b, Rajendra Pradeepa b, Mohan Deepa b, Ranjit Unnikrishnan a, Viswanathan Mohan a
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00291-7
Volume 11, Issue 12, December 2023, Pages 892-894
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00290-5
Volume 11, Issue 12, December 2023, Page 894
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial
doi : 10.1016/S2213-8587(23)00289-9
Volume 11, Issue 12, December 2023, Pages 894-895
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply
doi : 10.1016/S2213-8587(23)00292-9
Volume 11, Issue 12, December 2023, Pages 895-896
Metabolic non-communicable diseases in India: time to act
doi : 10.1016/S2213-8587(23)00297-8
Volume 11, Issue 12, December 2023, Pages 896-897
Metabolic non-communicable diseases in India: time to act
doi : 10.1016/S2213-8587(23)00298-X
Volume 11, Issue 12, December 2023, Pages 897-898
Metabolic non-communicable diseases in India: time to act – Authors' reply
doi : 10.1016/S2213-8587(23)00296-6
Volume 11, Issue 12, December 2023, Pages 898-899
Making adjustments: diabetes and developmental disability
Talha Burki
Iodine status in Iran: from deficient to replete
Fereidoun Azizi a, Hossein Delshad a, Mehdi Hedayati b, Parvin Mirmiran c
Correction to Lancet Diabetes Endocrinol 2023; 11: 720–30
doi : 10.1016/S2213-8587(23)00319-4
Volume 11, Issue 12, December 2023, Page e14
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
doi : 10.1016/S2213-8587(23)00253-X
Volume 11, Issue 12, December 2023, Pages 905-914
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
doi : 10.1016/S2213-8587(23)00267-X
Volume 11, Issue 12, December 2023, Pages 915-925
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease
Claudia Barth PhD a b, Arielle Crestol MS a b, Ann-Marie G de Lange PhD c d e, Prof Liisa A M Galea PhD f g
Catecholamine-induced hypertensive crises: current insights and management
Matthew A Nazari MD a, Rockyb Hasan MD a, Prof Mark Haigney MD b c, Alireza Maghsoudi MD d, Prof Jacques W M Lenders MD PhD e f, Prof Robert M Carey MD g, Prof Karel Pacak MD PhD a
